Scarica l'app Stockscreener
1.74
3.57%
0.06
Dopo l'orario di chiusura:
1.76
0.02
+1.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.68
Aprire:
$1.68
Volume 24 ore:
80,198
Relative Volume:
0.28
Capitalizzazione di mercato:
$9.58M
Reddito:
$468.00K
Utile/perdita netta:
$-10.34M
Rapporto P/E:
-0.2468
EPS:
-7.05
Flusso di cassa netto:
$-8.94M
1 W Prestazione:
-3.87%
1M Prestazione:
-27.20%
6M Prestazione:
-33.84%
1 anno Prestazione:
-31.28%
Intervallo 1D:
$1.68
$1.7664
Intervallo di 1 settimana:
$1.65
$1.8499
Portata 52W:
$1.625
$4.66
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Confronta BCDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
0.93 | 1.13B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.30 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.62 | 115.41M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1533 | 331.46M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.34 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
BioCardia Inc. Breaks Below Key Support LevelOversold Recovery Opportunity Stocks Attract Buyers - 선데이타임즈
Biocardia CEO Peter Altman acquires $1,488 in common stock - MSN
BioCardia (BCDA) CEO Altman buys $700 in shares By Investing.com - Investing.com Australia
BioCardia outlines regulatory milestones and targets FDA and PMDA submissions for CardiAMP and Helix in Q4 2025 - MSN
Biocardia 2024 Q2 Earnings Improved Losses Amidst Revenue Decline - AInvest
Real time breakdown of BioCardia Inc. stock performanceFree Fast Gaining Stock Screener Report - Newser
BioCardia sets Q4 2025 for FDA and PMDA submissions for CardiAMP and Helix trials. - AInvest
BioCardia Advances Clinical Trials Amid Financial Challenges - TipRanks
How BioCardia Inc. stock performs during market volatility5-Year Price Trend Summary and Analysis - Newser
BioCardia (BCDA) Advances with Promising Trial Results and Strat - GuruFocus
BioCardia's (BCDA) Q2 2025 Earnings and Strategic Pivots in Cardiac Regeneration: A Deep Dive into Long-Term Investment Potential - AInvest
BioCardia's 2025 Q2 Earnings Call: Navigating Contradictions in CardiAMP's Regulatory Journey - AInvest
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses By Investing.com - Investing.com Nigeria
Earnings call transcript: BioCardia Q2 2025 reveals increased R&D expenses - Investing.com
BioCardia Reports Q2 GAAP EPS of -$0.40, Net Cash Used in Operations Increases - AInvest
BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - The Manila Times
BioCardia Narrows Loss in Fiscal Q2 - The Globe and Mail
BioCardia, Inc. SEC 10-Q Report - TradingView
BioCardia Reports Q2 2025 Business Highlights, Seeks FDA Approval for CardiAMP System - AInvest
BioCardia's CardiAMP Cell Therapy Achieves Key Endpoints in Phase 3 Heart Failure Trial, FDA Meeting Ahead - Stock Titan
Full technical analysis of BioCardia Inc. stockFree Verified Signal From Chart Patterns - Newser
Is BioCardia Inc. meeting your algorithmic filter criteriaPredictive Screener for Daily Trade Watch - Newser
Can momentum traders help lift BioCardia Inc.Chart Confirmation Setup with ROI Signals - Newser
Should you wait for a breakout in BioCardia Inc.Capital Safe Picks with Consistent Gains - Newser
Is BioCardia Inc. forming a reversal patternFundamental + Technical Combined Watchlist - Newser
Real time social sentiment graph for BioCardia Inc.AI Pattern Recognition and Trade Prediction - Newser
Is BioCardia Inc. still worth holding after the dipEntry Opportunity Screener with Confirmation - Newser
What institutional flow reveals about BioCardia Inc.Free Chart Alert System With Entry Targets - Newser
Can BioCardia Inc. recover in the next quarterMarket Sentiment Tracker with Smart Alerts - Newser
BioCardia Inc.’s volatility index tracking explainedVolume Spike Detection for Early Breakouts - Newser
Using data tools to time your BioCardia Inc. exitMomentum-Based Prediction for Quick Returns - Newser
BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - The Globe and Mail
Has BioCardia Inc. formed a bullish divergenceFree News Based Entry Opportunity Alerts - Newser
What candlestick patterns are forming on BioCardia Inc.Day Trading Setup Forecast with Trend Model - Newser
Biocardia BCDA 2025Q2 Earnings Preview Upside Ahead on Strategic Product Developments - AInvest
BioCardia to Host Q2 2025 Earnings Call on August 11 - AInvest
BioCardia Inc expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Earnings Preview: BioCardia to Report Financial Results Post-market on August 11 - 富途牛牛
BioCardia Announces Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - AInvest
Cellular Therapeutics Pioneer BioCardia Announces Q2 2025 Earnings and Pipeline Update - Stock Titan
TR | OpenAI4o Initiates BioCardia(BCDA.US) With Hold Rating, Announces Target Price $2 - 富途牛牛
What recovery options are there for BioCardia Inc.Weekly High Conviction Trade Setup Analysis - Newser
Will breakout in BioCardia Inc. lead to full recoveryVolatility Analysis and Entry Risk Mapping - Newser
BioCardia Reveals Plans to Request Meeting With FDA Regarding CardiAMP Heart Failure Cell Therapy - CGTLive®
BioCardia Seeks FDA Approval for CardiAMP and Helix Transendocardial Delivery Catheter - AInvest
New Strong Sell Stocks for August 5th - The Globe and Mail
Biocardia Stock Plunges 12.76% Amid Market Volatility - AInvest
Biocardia, Inc. shares fall 12.76% premarket after providing update on regulatory approvals. - AInvest
Biocardia, Inc. shares fall 5.61% premarket after providing update on regulatory activities. - AInvest
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):